Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Core Insights - Pyxis Oncology, Inc. is focused on developing next-generation therapeutics for difficult-to-treat cancers [5] - The company has granted restricted stock units and stock options to five newly hired employees as part of its 2022 Inducement Plan [1][2] Employee Compensation - A total of 89,530 restricted stock units and 111,913 stock options were granted to new employees [1] - The stock options have a ten-year term with an exercise price of $3.31, which is the closing price of the company's common stock on June 28, 2024 [2] - The vesting schedule for the stock options includes 25% vesting on the first anniversary and the remaining shares vesting monthly over the following 36 months [2] Company Overview - Pyxis Oncology is a clinical-stage company developing therapeutics such as PYX-201 and PYX-106, targeting solid tumors [5] - The company's therapeutic candidates aim to directly kill tumor cells and address cancer-related pathologies that contribute to proliferation and immune evasion [5] - Pyxis Oncology employs novel strategies in its antibody-drug conjugate and immuno-oncology programs to target a wide range of solid tumors resistant to current treatments [5]